A vs. UNH: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at A and UNH, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Overview
UNH’s market capitalization of 279.90 billion USD is significantly greater than A’s 34.48 billion USD, highlighting its more substantial market valuation.
A’s beta of 1.23 points to significantly higher volatility compared to UNH (beta: 0.45), suggesting A has greater potential for both gains and losses relative to market movements.
| Symbol | A | UNH |
|---|---|---|
| Company Name | Agilent Technologies, Inc. | UnitedHealth Group Incorporated |
| Country | US | US |
| Sector | Healthcare | Healthcare |
| Industry | Medical - Diagnostics & Research | Medical - Healthcare Plans |
| CEO | Padraig McDonnell | Stephen J. Hemsley |
| Price | 121.38 USD | 308.55 USD |
| Market Cap | 34.48 billion USD | 279.90 billion USD |
| Beta | 1.23 | 0.45 |
| Exchange | NYSE | NYSE |
| IPO Date | November 18, 1999 | October 17, 1984 |
| ADR | No | No |
Historical Performance
This chart compares the performance of A and UNH by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period.
Data is adjusted for dividends and splits.
Profitability
Return on Equity
A
19.46%
Medical - Diagnostics & Research Industry
- Max
- 57.35%
- Q3
- 18.17%
- Median
- 2.69%
- Q1
- -16.72%
- Min
- -48.78%
In the upper quartile for the Medical - Diagnostics & Research industry, A’s Return on Equity of 19.46% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
UNH
24.09%
Medical - Healthcare Plans Industry
- Max
- 13.94%
- Q3
- 13.62%
- Median
- 11.42%
- Q1
- 7.74%
- Min
- 6.98%
UNH’s Return on Equity of 24.09% is exceptionally high, placing it well beyond the typical range for the Medical - Healthcare Plans industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
Return on Invested Capital
A
11.71%
Medical - Diagnostics & Research Industry
- Max
- 42.99%
- Q3
- 11.55%
- Median
- 3.02%
- Q1
- -11.49%
- Min
- -40.79%
In the upper quartile for the Medical - Diagnostics & Research industry, A’s Return on Invested Capital of 11.71% signifies a highly effective use of its capital to generate profits when compared to its peers.
UNH
13.21%
Medical - Healthcare Plans Industry
- Max
- 15.50%
- Q3
- 7.12%
- Median
- 5.48%
- Q1
- -3.47%
- Min
- -15.02%
In the upper quartile for the Medical - Healthcare Plans industry, UNH’s Return on Invested Capital of 13.21% signifies a highly effective use of its capital to generate profits when compared to its peers.
Net Profit Margin
A
17.59%
Medical - Diagnostics & Research Industry
- Max
- 22.76%
- Q3
- 15.19%
- Median
- 1.64%
- Q1
- -22.25%
- Min
- -78.24%
A Net Profit Margin of 17.59% places A in the upper quartile for the Medical - Diagnostics & Research industry, signifying strong profitability and more effective cost management than most of its peers.
UNH
5.43%
Medical - Healthcare Plans Industry
- Max
- 3.23%
- Q3
- 2.62%
- Median
- 1.70%
- Q1
- 1.27%
- Min
- 1.22%
UNH’s Net Profit Margin of 5.43% is exceptionally high, placing it well beyond the typical range for the Medical - Healthcare Plans industry. This demonstrates outstanding operational efficiency and a strong competitive advantage in converting revenue into profit.
Operating Profit Margin
A
21.38%
Medical - Diagnostics & Research Industry
- Max
- 36.06%
- Q3
- 20.26%
- Median
- 6.15%
- Q1
- -21.89%
- Min
- -82.21%
An Operating Profit Margin of 21.38% places A in the upper quartile for the Medical - Diagnostics & Research industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
UNH
8.22%
Medical - Healthcare Plans Industry
- Max
- 4.30%
- Q3
- 3.77%
- Median
- 2.61%
- Q1
- 1.60%
- Min
- -1.64%
UNH’s Operating Profit Margin of 8.22% is exceptionally high, placing it well above the typical range for the Medical - Healthcare Plans industry. This demonstrates outstanding efficiency in managing its core operations, which can be a result of strong pricing power or superior cost control.
Profitability at a Glance
| Symbol | A | UNH |
|---|---|---|
| Return on Equity (TTM) | 19.46% | 24.09% |
| Return on Assets (TTM) | 9.59% | 7.14% |
| Return on Invested Capital (TTM) | 11.71% | 13.21% |
| Net Profit Margin (TTM) | 17.59% | 5.43% |
| Operating Profit Margin (TTM) | 21.38% | 8.22% |
| Gross Profit Margin (TTM) | 53.79% | 21.48% |
Financial Strength
Current Ratio
A
2.09
Medical - Diagnostics & Research Industry
- Max
- 6.91
- Q3
- 4.11
- Median
- 2.46
- Q1
- 1.44
- Min
- 0.73
A’s Current Ratio of 2.09 aligns with the median group of the Medical - Diagnostics & Research industry, indicating that its short-term liquidity is in line with its sector peers.
UNH
0.85
Medical - Healthcare Plans Industry
- Max
- 1.91
- Q3
- 1.63
- Median
- 1.43
- Q1
- 0.85
- Min
- 0.78
UNH’s Current Ratio of 0.85 aligns with the median group of the Medical - Healthcare Plans industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio
A
0.57
Medical - Diagnostics & Research Industry
- Max
- 1.10
- Q3
- 0.82
- Median
- 0.39
- Q1
- 0.21
- Min
- 0.01
A’s Debt-to-Equity Ratio of 0.57 is typical for the Medical - Diagnostics & Research industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
UNH
0.86
Medical - Healthcare Plans Industry
- Max
- 1.06
- Q3
- 0.86
- Median
- 0.75
- Q1
- 0.66
- Min
- 0.66
UNH’s Debt-to-Equity Ratio of 0.86 is typical for the Medical - Healthcare Plans industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio
A
-472.33
Medical - Diagnostics & Research Industry
- Max
- 37.07
- Q3
- 5.62
- Median
- 1.76
- Q1
- -38.78
- Min
- -57.46
A has a negative Interest Coverage Ratio of -472.33. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
UNH
16.30
Medical - Healthcare Plans Industry
- Max
- 6.23
- Q3
- 6.23
- Median
- 5.19
- Q1
- 4.64
- Min
- 3.18
With an Interest Coverage Ratio of 16.30, UNH demonstrates a superior capacity to service its debt, placing it well above the typical range for the Medical - Healthcare Plans industry. This stems from either robust earnings or a conservative debt load.
Financial Strength at a Glance
| Symbol | A | UNH |
|---|---|---|
| Current Ratio (TTM) | 2.09 | 0.85 |
| Quick Ratio (TTM) | 1.60 | 0.85 |
| Debt-to-Equity Ratio (TTM) | 0.57 | 0.86 |
| Debt-to-Asset Ratio (TTM) | 0.29 | 0.26 |
| Net Debt-to-EBITDA Ratio (TTM) | 1.43 | 1.57 |
| Interest Coverage Ratio (TTM) | -472.33 | 16.30 |
Growth
The following charts compare key year-over-year (YoY) growth metrics for A and UNH. These metrics are based on the companies’ annual financial reports.
Revenue Growth
Earnings Per Share (EPS) Growth
Free Cash Flow Growth
Dividend
Dividend Yield
A
0.81%
Medical - Diagnostics & Research Industry
- Max
- 2.76%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
With a Dividend Yield of 0.81%, A offers a more attractive income stream than most of its peers in the Medical - Diagnostics & Research industry, signaling a strong commitment to shareholder returns.
UNH
2.76%
Medical - Healthcare Plans Industry
- Max
- 3.88%
- Q3
- 1.78%
- Median
- 0.73%
- Q1
- 0.00%
- Min
- 0.00%
With a Dividend Yield of 2.76%, UNH offers a more attractive income stream than most of its peers in the Medical - Healthcare Plans industry, signaling a strong commitment to shareholder returns.
Dividend Payout Ratio
A
23.76%
Medical - Diagnostics & Research Industry
- Max
- 37.46%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
A’s Dividend Payout Ratio of 23.76% is in the upper quartile for the Medical - Diagnostics & Research industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.
UNH
34.90%
Medical - Healthcare Plans Industry
- Max
- 63.88%
- Q3
- 29.91%
- Median
- 12.57%
- Q1
- 0.00%
- Min
- 0.00%
UNH’s Dividend Payout Ratio of 34.90% is in the upper quartile for the Medical - Healthcare Plans industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.
Dividend at a Glance
| Symbol | A | UNH |
|---|---|---|
| Dividend Yield (TTM) | 0.81% | 2.76% |
| Dividend Payout Ratio (TTM) | 23.76% | 34.90% |
Valuation
Price-to-Earnings Ratio
A
29.67
Medical - Diagnostics & Research Industry
- Max
- 48.28
- Q3
- 44.64
- Median
- 29.13
- Q1
- 22.34
- Min
- 15.59
A’s P/E Ratio of 29.67 is within the middle range for the Medical - Diagnostics & Research industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
UNH
12.81
Medical - Healthcare Plans Industry
- Max
- 18.17
- Q3
- 17.32
- Median
- 15.48
- Q1
- 13.55
- Min
- 12.84
UNH’s P/E Ratio of 12.81 is below the typical range for the Medical - Healthcare Plans industry. This may indicate that the stock is potentially undervalued, or it could reflect market concerns about the company’s future prospects.
Forward P/E to Growth Ratio
A
3.80
Medical - Diagnostics & Research Industry
- Max
- 4.18
- Q3
- 3.64
- Median
- 2.40
- Q1
- 0.57
- Min
- 0.04
A Forward PEG Ratio of 3.80 places A in the upper quartile for the Medical - Diagnostics & Research industry. This suggests the stock is potentially expensive compared to its peers relative to its growth forecast, which may warrant caution.
UNH
0.78
Medical - Healthcare Plans Industry
- Max
- 1.41
- Q3
- 1.09
- Median
- 0.85
- Q1
- 0.79
- Min
- 0.60
In the lower quartile for the Medical - Healthcare Plans industry, UNH’s Forward PEG Ratio of 0.78 is a positive indicator. It suggests that the stock may be attractively valued relative to its expected earnings growth.
Price-to-Sales Ratio
A
5.20
Medical - Diagnostics & Research Industry
- Max
- 12.53
- Q3
- 6.19
- Median
- 3.58
- Q1
- 1.95
- Min
- 0.58
A’s P/S Ratio of 5.20 aligns with the market consensus for the Medical - Diagnostics & Research industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
UNH
0.69
Medical - Healthcare Plans Industry
- Max
- 0.94
- Q3
- 0.64
- Median
- 0.43
- Q1
- 0.27
- Min
- 0.16
UNH’s P/S Ratio of 0.69 is in the upper echelon for the Medical - Healthcare Plans industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
Price-to-Book Ratio
A
5.64
Medical - Diagnostics & Research Industry
- Max
- 10.67
- Q3
- 5.74
- Median
- 2.95
- Q1
- 1.30
- Min
- 0.39
The P/B Ratio is often not a primary valuation metric for the Medical - Diagnostics & Research industry.
UNH
2.98
Medical - Healthcare Plans Industry
- Max
- 4.08
- Q3
- 3.83
- Median
- 2.63
- Q1
- 1.74
- Min
- 0.96
UNH’s P/B Ratio of 2.98 is within the conventional range for the Medical - Healthcare Plans industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | A | UNH |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 29.67 | 12.81 |
| Forward PEG Ratio (TTM) | 3.80 | 0.78 |
| Price-to-Sales Ratio (P/S, TTM) | 5.20 | 0.69 |
| Price-to-Book Ratio (P/B, TTM) | 5.64 | 2.98 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 24.63 | 11.26 |
| EV-to-EBITDA (TTM) | 25.95 | 10.28 |
| EV-to-Sales (TTM) | 5.51 | 0.81 |